



The Chinese University of Hong Kong
Non-confidential Abstract of Technology Disclosure

Title:

Detection of Hepatitis B virus mutations

CUHK Ref. No.:

09/MED/320

Inventor(s):

Professor Chunming DING, Centre for Emerging Infectious Diseases

Patent Status:

US Patent Pending

Non-confidential abstract:

Worldwide, it is estimated that 400 million people are chronically infected with hepatitis B virus (HBV). Chronic hepatitis B (CHB) infection is the commonest cause of liver cirrhosis and hepatocellular carcinoma (HCC), with an estimated 500,000-900,000 death per year. Continuing HBV replication increases the risk of progression to cirrhosis and HCC. Thus, antiviral therapy aiming at blocking virus replication is essential in managing CHB patients. A number of nucleos(t)ide analogues such as lamivudine, adefovir dipivoxil, telbivudine, entecavir and tenofovir are approved for antiviral treatment.

Unfortunately, HBV variations frequently develop with long-term antiviral therapy. Some of these variations confer drug resistance, resulting in treatment failure which may further lead to hepatitis reactivation and hepatic decompensation. Periodic HBV viral load quantification is commonly used to monitor antiviral treatment response and early detection of drug resistance. This invention disclose a method for direct detection of important HBV variations.

For further queries, please contact:

Mr Billy Lam
Technology Licensing Coordinator
Tel: (852) 2609 8882
Fax: (852) 2603 5451
Email: billylam@cuhk.edu.hk

Address:
Technology Licensing Office
The Chinese University of Hong Kong
Room 328, Pi Ch'iu Bldg, Shatin, New Territories
Hong Kong SAR